Autoimmune disease and vaccination: impact on infectious disease prevention and a look at future applications
Vaccines hold promise both for the prevention of infections and as potential immunologic therapy for patients with autoimmune disease (AD). These patients are at high risk for both common and opportunistic infections, but this risk can be significantly reduced and even obviated with the use of recom...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
McKinnon, John E. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2016transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
15 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Growth of organic benzimidazole (BMZ) single crystal by vertical Bridgman technique and its structural, spectral, thermal, optical, mechanical and dielectric properties - Muthuraja, A. ELSEVIER, 2015, the journal of laboratory and clinical medicine : the official publication of the Central Society for Clinical Research, New York, NY |
|---|---|
| Übergeordnetes Werk: |
volume:167 ; year:2016 ; number:1 ; pages:46-60 ; extent:15 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.trsl.2015.08.008 |
|---|
| Katalog-ID: |
ELV035320710 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV035320710 | ||
| 003 | DE-627 | ||
| 005 | 20230625203853.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.trsl.2015.08.008 |2 doi | |
| 028 | 5 | 2 | |a GBVA2016011000018.pica |
| 035 | |a (DE-627)ELV035320710 | ||
| 035 | |a (ELSEVIER)S1931-5244(15)00294-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 530 |q VZ |
| 082 | 0 | 4 | |a 620 |q VZ |
| 082 | 0 | 4 | |a 670 |q VZ |
| 082 | 0 | 4 | |a 300 |q VZ |
| 084 | |a 70.00 |2 bkl | ||
| 084 | |a 71.00 |2 bkl | ||
| 100 | 1 | |a McKinnon, John E. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Autoimmune disease and vaccination: impact on infectious disease prevention and a look at future applications |
| 264 | 1 | |c 2016transfer abstract | |
| 300 | |a 15 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Vaccines hold promise both for the prevention of infections and as potential immunologic therapy for patients with autoimmune disease (AD). These patients are at high risk for both common and opportunistic infections, but this risk can be significantly reduced and even obviated with the use of recommended available vaccines. Unfortunately, patients with ADs are not routinely offered or provided indicated vaccinations and have higher rates of complications from vaccine-preventable illnesses than patients without ADs. In addition, vaccine therapy is currently under study for the treatment of autoimmune disorders, with early studies demonstrating immunomodulatory effects that may counter undesired immune activation and alleviate disease activity. | ||
| 520 | |a Vaccines hold promise both for the prevention of infections and as potential immunologic therapy for patients with autoimmune disease (AD). These patients are at high risk for both common and opportunistic infections, but this risk can be significantly reduced and even obviated with the use of recommended available vaccines. Unfortunately, patients with ADs are not routinely offered or provided indicated vaccinations and have higher rates of complications from vaccine-preventable illnesses than patients without ADs. In addition, vaccine therapy is currently under study for the treatment of autoimmune disorders, with early studies demonstrating immunomodulatory effects that may counter undesired immune activation and alleviate disease activity. | ||
| 650 | 7 | |a MMRV |2 Elsevier | |
| 650 | 7 | |a CDC |2 Elsevier | |
| 650 | 7 | |a RNA |2 Elsevier | |
| 650 | 7 | |a TCV |2 Elsevier | |
| 650 | 7 | |a APLs |2 Elsevier | |
| 650 | 7 | |a IgG |2 Elsevier | |
| 650 | 7 | |a DM |2 Elsevier | |
| 650 | 7 | |a CAPITA |2 Elsevier | |
| 650 | 7 | |a IBD |2 Elsevier | |
| 650 | 7 | |a SLE |2 Elsevier | |
| 650 | 7 | |a TNF |2 Elsevier | |
| 650 | 7 | |a IgM |2 Elsevier | |
| 650 | 7 | |a HPV |2 Elsevier | |
| 650 | 7 | |a SLEDAI |2 Elsevier | |
| 650 | 7 | |a HZ |2 Elsevier | |
| 650 | 7 | |a ASIA |2 Elsevier | |
| 650 | 7 | |a ANCA |2 Elsevier | |
| 650 | 7 | |a RNP |2 Elsevier | |
| 650 | 7 | |a ACIP |2 Elsevier | |
| 650 | 7 | |a Tdap |2 Elsevier | |
| 650 | 7 | |a GBS |2 Elsevier | |
| 650 | 7 | |a MBP |2 Elsevier | |
| 650 | 7 | |a HBV |2 Elsevier | |
| 650 | 7 | |a Hib |2 Elsevier | |
| 650 | 7 | |a PCV13 |2 Elsevier | |
| 650 | 7 | |a AD |2 Elsevier | |
| 650 | 7 | |a PBV |2 Elsevier | |
| 650 | 7 | |a MS |2 Elsevier | |
| 650 | 7 | |a EAE |2 Elsevier | |
| 650 | 7 | |a IS |2 Elsevier | |
| 650 | 7 | |a IL-10 |2 Elsevier | |
| 650 | 7 | |a VE |2 Elsevier | |
| 650 | 7 | |a RA |2 Elsevier | |
| 650 | 7 | |a ACR |2 Elsevier | |
| 650 | 7 | |a TGF |2 Elsevier | |
| 650 | 7 | |a MMR |2 Elsevier | |
| 650 | 7 | |a HIV |2 Elsevier | |
| 650 | 7 | |a EULAR |2 Elsevier | |
| 650 | 7 | |a PSV23 |2 Elsevier | |
| 650 | 7 | |a PCP |2 Elsevier | |
| 650 | 7 | |a DC |2 Elsevier | |
| 700 | 1 | |a Maksimowicz-McKinnon, Kathleen |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |a Muthuraja, A. ELSEVIER |t Growth of organic benzimidazole (BMZ) single crystal by vertical Bridgman technique and its structural, spectral, thermal, optical, mechanical and dielectric properties |d 2015 |d the journal of laboratory and clinical medicine : the official publication of the Central Society for Clinical Research |g New York, NY |w (DE-627)ELV013179047 |
| 773 | 1 | 8 | |g volume:167 |g year:2016 |g number:1 |g pages:46-60 |g extent:15 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.trsl.2015.08.008 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 936 | b | k | |a 70.00 |j Sozialwissenschaften allgemein: Allgemeines |q VZ |
| 936 | b | k | |a 71.00 |j Soziologie: Allgemeines |q VZ |
| 951 | |a AR | ||
| 952 | |d 167 |j 2016 |e 1 |h 46-60 |g 15 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
j e m je jem |
|---|---|
| matchkey_str |
mckinnonjohnemaksimowiczmckinnonkathleen:2016----:uomueiesadacntoipcoifciudsaervninn |
| hierarchy_sort_str |
2016transfer abstract |
| bklnumber |
70.00 71.00 |
| publishDate |
2016 |
| allfields |
10.1016/j.trsl.2015.08.008 doi GBVA2016011000018.pica (DE-627)ELV035320710 (ELSEVIER)S1931-5244(15)00294-7 DE-627 ger DE-627 rakwb eng 610 610 DE-600 530 VZ 620 VZ 670 VZ 300 VZ 70.00 bkl 71.00 bkl McKinnon, John E. verfasserin aut Autoimmune disease and vaccination: impact on infectious disease prevention and a look at future applications 2016transfer abstract 15 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Vaccines hold promise both for the prevention of infections and as potential immunologic therapy for patients with autoimmune disease (AD). These patients are at high risk for both common and opportunistic infections, but this risk can be significantly reduced and even obviated with the use of recommended available vaccines. Unfortunately, patients with ADs are not routinely offered or provided indicated vaccinations and have higher rates of complications from vaccine-preventable illnesses than patients without ADs. In addition, vaccine therapy is currently under study for the treatment of autoimmune disorders, with early studies demonstrating immunomodulatory effects that may counter undesired immune activation and alleviate disease activity. Vaccines hold promise both for the prevention of infections and as potential immunologic therapy for patients with autoimmune disease (AD). These patients are at high risk for both common and opportunistic infections, but this risk can be significantly reduced and even obviated with the use of recommended available vaccines. Unfortunately, patients with ADs are not routinely offered or provided indicated vaccinations and have higher rates of complications from vaccine-preventable illnesses than patients without ADs. In addition, vaccine therapy is currently under study for the treatment of autoimmune disorders, with early studies demonstrating immunomodulatory effects that may counter undesired immune activation and alleviate disease activity. MMRV Elsevier CDC Elsevier RNA Elsevier TCV Elsevier APLs Elsevier IgG Elsevier DM Elsevier CAPITA Elsevier IBD Elsevier SLE Elsevier TNF Elsevier IgM Elsevier HPV Elsevier SLEDAI Elsevier HZ Elsevier ASIA Elsevier ANCA Elsevier RNP Elsevier ACIP Elsevier Tdap Elsevier GBS Elsevier MBP Elsevier HBV Elsevier Hib Elsevier PCV13 Elsevier AD Elsevier PBV Elsevier MS Elsevier EAE Elsevier IS Elsevier IL-10 Elsevier VE Elsevier RA Elsevier ACR Elsevier TGF Elsevier MMR Elsevier HIV Elsevier EULAR Elsevier PSV23 Elsevier PCP Elsevier DC Elsevier Maksimowicz-McKinnon, Kathleen oth Enthalten in Elsevier Muthuraja, A. ELSEVIER Growth of organic benzimidazole (BMZ) single crystal by vertical Bridgman technique and its structural, spectral, thermal, optical, mechanical and dielectric properties 2015 the journal of laboratory and clinical medicine : the official publication of the Central Society for Clinical Research New York, NY (DE-627)ELV013179047 volume:167 year:2016 number:1 pages:46-60 extent:15 https://doi.org/10.1016/j.trsl.2015.08.008 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 70.00 Sozialwissenschaften allgemein: Allgemeines VZ 71.00 Soziologie: Allgemeines VZ AR 167 2016 1 46-60 15 045F 610 |
| spelling |
10.1016/j.trsl.2015.08.008 doi GBVA2016011000018.pica (DE-627)ELV035320710 (ELSEVIER)S1931-5244(15)00294-7 DE-627 ger DE-627 rakwb eng 610 610 DE-600 530 VZ 620 VZ 670 VZ 300 VZ 70.00 bkl 71.00 bkl McKinnon, John E. verfasserin aut Autoimmune disease and vaccination: impact on infectious disease prevention and a look at future applications 2016transfer abstract 15 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Vaccines hold promise both for the prevention of infections and as potential immunologic therapy for patients with autoimmune disease (AD). These patients are at high risk for both common and opportunistic infections, but this risk can be significantly reduced and even obviated with the use of recommended available vaccines. Unfortunately, patients with ADs are not routinely offered or provided indicated vaccinations and have higher rates of complications from vaccine-preventable illnesses than patients without ADs. In addition, vaccine therapy is currently under study for the treatment of autoimmune disorders, with early studies demonstrating immunomodulatory effects that may counter undesired immune activation and alleviate disease activity. Vaccines hold promise both for the prevention of infections and as potential immunologic therapy for patients with autoimmune disease (AD). These patients are at high risk for both common and opportunistic infections, but this risk can be significantly reduced and even obviated with the use of recommended available vaccines. Unfortunately, patients with ADs are not routinely offered or provided indicated vaccinations and have higher rates of complications from vaccine-preventable illnesses than patients without ADs. In addition, vaccine therapy is currently under study for the treatment of autoimmune disorders, with early studies demonstrating immunomodulatory effects that may counter undesired immune activation and alleviate disease activity. MMRV Elsevier CDC Elsevier RNA Elsevier TCV Elsevier APLs Elsevier IgG Elsevier DM Elsevier CAPITA Elsevier IBD Elsevier SLE Elsevier TNF Elsevier IgM Elsevier HPV Elsevier SLEDAI Elsevier HZ Elsevier ASIA Elsevier ANCA Elsevier RNP Elsevier ACIP Elsevier Tdap Elsevier GBS Elsevier MBP Elsevier HBV Elsevier Hib Elsevier PCV13 Elsevier AD Elsevier PBV Elsevier MS Elsevier EAE Elsevier IS Elsevier IL-10 Elsevier VE Elsevier RA Elsevier ACR Elsevier TGF Elsevier MMR Elsevier HIV Elsevier EULAR Elsevier PSV23 Elsevier PCP Elsevier DC Elsevier Maksimowicz-McKinnon, Kathleen oth Enthalten in Elsevier Muthuraja, A. ELSEVIER Growth of organic benzimidazole (BMZ) single crystal by vertical Bridgman technique and its structural, spectral, thermal, optical, mechanical and dielectric properties 2015 the journal of laboratory and clinical medicine : the official publication of the Central Society for Clinical Research New York, NY (DE-627)ELV013179047 volume:167 year:2016 number:1 pages:46-60 extent:15 https://doi.org/10.1016/j.trsl.2015.08.008 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 70.00 Sozialwissenschaften allgemein: Allgemeines VZ 71.00 Soziologie: Allgemeines VZ AR 167 2016 1 46-60 15 045F 610 |
| allfields_unstemmed |
10.1016/j.trsl.2015.08.008 doi GBVA2016011000018.pica (DE-627)ELV035320710 (ELSEVIER)S1931-5244(15)00294-7 DE-627 ger DE-627 rakwb eng 610 610 DE-600 530 VZ 620 VZ 670 VZ 300 VZ 70.00 bkl 71.00 bkl McKinnon, John E. verfasserin aut Autoimmune disease and vaccination: impact on infectious disease prevention and a look at future applications 2016transfer abstract 15 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Vaccines hold promise both for the prevention of infections and as potential immunologic therapy for patients with autoimmune disease (AD). These patients are at high risk for both common and opportunistic infections, but this risk can be significantly reduced and even obviated with the use of recommended available vaccines. Unfortunately, patients with ADs are not routinely offered or provided indicated vaccinations and have higher rates of complications from vaccine-preventable illnesses than patients without ADs. In addition, vaccine therapy is currently under study for the treatment of autoimmune disorders, with early studies demonstrating immunomodulatory effects that may counter undesired immune activation and alleviate disease activity. Vaccines hold promise both for the prevention of infections and as potential immunologic therapy for patients with autoimmune disease (AD). These patients are at high risk for both common and opportunistic infections, but this risk can be significantly reduced and even obviated with the use of recommended available vaccines. Unfortunately, patients with ADs are not routinely offered or provided indicated vaccinations and have higher rates of complications from vaccine-preventable illnesses than patients without ADs. In addition, vaccine therapy is currently under study for the treatment of autoimmune disorders, with early studies demonstrating immunomodulatory effects that may counter undesired immune activation and alleviate disease activity. MMRV Elsevier CDC Elsevier RNA Elsevier TCV Elsevier APLs Elsevier IgG Elsevier DM Elsevier CAPITA Elsevier IBD Elsevier SLE Elsevier TNF Elsevier IgM Elsevier HPV Elsevier SLEDAI Elsevier HZ Elsevier ASIA Elsevier ANCA Elsevier RNP Elsevier ACIP Elsevier Tdap Elsevier GBS Elsevier MBP Elsevier HBV Elsevier Hib Elsevier PCV13 Elsevier AD Elsevier PBV Elsevier MS Elsevier EAE Elsevier IS Elsevier IL-10 Elsevier VE Elsevier RA Elsevier ACR Elsevier TGF Elsevier MMR Elsevier HIV Elsevier EULAR Elsevier PSV23 Elsevier PCP Elsevier DC Elsevier Maksimowicz-McKinnon, Kathleen oth Enthalten in Elsevier Muthuraja, A. ELSEVIER Growth of organic benzimidazole (BMZ) single crystal by vertical Bridgman technique and its structural, spectral, thermal, optical, mechanical and dielectric properties 2015 the journal of laboratory and clinical medicine : the official publication of the Central Society for Clinical Research New York, NY (DE-627)ELV013179047 volume:167 year:2016 number:1 pages:46-60 extent:15 https://doi.org/10.1016/j.trsl.2015.08.008 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 70.00 Sozialwissenschaften allgemein: Allgemeines VZ 71.00 Soziologie: Allgemeines VZ AR 167 2016 1 46-60 15 045F 610 |
| allfieldsGer |
10.1016/j.trsl.2015.08.008 doi GBVA2016011000018.pica (DE-627)ELV035320710 (ELSEVIER)S1931-5244(15)00294-7 DE-627 ger DE-627 rakwb eng 610 610 DE-600 530 VZ 620 VZ 670 VZ 300 VZ 70.00 bkl 71.00 bkl McKinnon, John E. verfasserin aut Autoimmune disease and vaccination: impact on infectious disease prevention and a look at future applications 2016transfer abstract 15 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Vaccines hold promise both for the prevention of infections and as potential immunologic therapy for patients with autoimmune disease (AD). These patients are at high risk for both common and opportunistic infections, but this risk can be significantly reduced and even obviated with the use of recommended available vaccines. Unfortunately, patients with ADs are not routinely offered or provided indicated vaccinations and have higher rates of complications from vaccine-preventable illnesses than patients without ADs. In addition, vaccine therapy is currently under study for the treatment of autoimmune disorders, with early studies demonstrating immunomodulatory effects that may counter undesired immune activation and alleviate disease activity. Vaccines hold promise both for the prevention of infections and as potential immunologic therapy for patients with autoimmune disease (AD). These patients are at high risk for both common and opportunistic infections, but this risk can be significantly reduced and even obviated with the use of recommended available vaccines. Unfortunately, patients with ADs are not routinely offered or provided indicated vaccinations and have higher rates of complications from vaccine-preventable illnesses than patients without ADs. In addition, vaccine therapy is currently under study for the treatment of autoimmune disorders, with early studies demonstrating immunomodulatory effects that may counter undesired immune activation and alleviate disease activity. MMRV Elsevier CDC Elsevier RNA Elsevier TCV Elsevier APLs Elsevier IgG Elsevier DM Elsevier CAPITA Elsevier IBD Elsevier SLE Elsevier TNF Elsevier IgM Elsevier HPV Elsevier SLEDAI Elsevier HZ Elsevier ASIA Elsevier ANCA Elsevier RNP Elsevier ACIP Elsevier Tdap Elsevier GBS Elsevier MBP Elsevier HBV Elsevier Hib Elsevier PCV13 Elsevier AD Elsevier PBV Elsevier MS Elsevier EAE Elsevier IS Elsevier IL-10 Elsevier VE Elsevier RA Elsevier ACR Elsevier TGF Elsevier MMR Elsevier HIV Elsevier EULAR Elsevier PSV23 Elsevier PCP Elsevier DC Elsevier Maksimowicz-McKinnon, Kathleen oth Enthalten in Elsevier Muthuraja, A. ELSEVIER Growth of organic benzimidazole (BMZ) single crystal by vertical Bridgman technique and its structural, spectral, thermal, optical, mechanical and dielectric properties 2015 the journal of laboratory and clinical medicine : the official publication of the Central Society for Clinical Research New York, NY (DE-627)ELV013179047 volume:167 year:2016 number:1 pages:46-60 extent:15 https://doi.org/10.1016/j.trsl.2015.08.008 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 70.00 Sozialwissenschaften allgemein: Allgemeines VZ 71.00 Soziologie: Allgemeines VZ AR 167 2016 1 46-60 15 045F 610 |
| allfieldsSound |
10.1016/j.trsl.2015.08.008 doi GBVA2016011000018.pica (DE-627)ELV035320710 (ELSEVIER)S1931-5244(15)00294-7 DE-627 ger DE-627 rakwb eng 610 610 DE-600 530 VZ 620 VZ 670 VZ 300 VZ 70.00 bkl 71.00 bkl McKinnon, John E. verfasserin aut Autoimmune disease and vaccination: impact on infectious disease prevention and a look at future applications 2016transfer abstract 15 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Vaccines hold promise both for the prevention of infections and as potential immunologic therapy for patients with autoimmune disease (AD). These patients are at high risk for both common and opportunistic infections, but this risk can be significantly reduced and even obviated with the use of recommended available vaccines. Unfortunately, patients with ADs are not routinely offered or provided indicated vaccinations and have higher rates of complications from vaccine-preventable illnesses than patients without ADs. In addition, vaccine therapy is currently under study for the treatment of autoimmune disorders, with early studies demonstrating immunomodulatory effects that may counter undesired immune activation and alleviate disease activity. Vaccines hold promise both for the prevention of infections and as potential immunologic therapy for patients with autoimmune disease (AD). These patients are at high risk for both common and opportunistic infections, but this risk can be significantly reduced and even obviated with the use of recommended available vaccines. Unfortunately, patients with ADs are not routinely offered or provided indicated vaccinations and have higher rates of complications from vaccine-preventable illnesses than patients without ADs. In addition, vaccine therapy is currently under study for the treatment of autoimmune disorders, with early studies demonstrating immunomodulatory effects that may counter undesired immune activation and alleviate disease activity. MMRV Elsevier CDC Elsevier RNA Elsevier TCV Elsevier APLs Elsevier IgG Elsevier DM Elsevier CAPITA Elsevier IBD Elsevier SLE Elsevier TNF Elsevier IgM Elsevier HPV Elsevier SLEDAI Elsevier HZ Elsevier ASIA Elsevier ANCA Elsevier RNP Elsevier ACIP Elsevier Tdap Elsevier GBS Elsevier MBP Elsevier HBV Elsevier Hib Elsevier PCV13 Elsevier AD Elsevier PBV Elsevier MS Elsevier EAE Elsevier IS Elsevier IL-10 Elsevier VE Elsevier RA Elsevier ACR Elsevier TGF Elsevier MMR Elsevier HIV Elsevier EULAR Elsevier PSV23 Elsevier PCP Elsevier DC Elsevier Maksimowicz-McKinnon, Kathleen oth Enthalten in Elsevier Muthuraja, A. ELSEVIER Growth of organic benzimidazole (BMZ) single crystal by vertical Bridgman technique and its structural, spectral, thermal, optical, mechanical and dielectric properties 2015 the journal of laboratory and clinical medicine : the official publication of the Central Society for Clinical Research New York, NY (DE-627)ELV013179047 volume:167 year:2016 number:1 pages:46-60 extent:15 https://doi.org/10.1016/j.trsl.2015.08.008 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 70.00 Sozialwissenschaften allgemein: Allgemeines VZ 71.00 Soziologie: Allgemeines VZ AR 167 2016 1 46-60 15 045F 610 |
| language |
English |
| source |
Enthalten in Growth of organic benzimidazole (BMZ) single crystal by vertical Bridgman technique and its structural, spectral, thermal, optical, mechanical and dielectric properties New York, NY volume:167 year:2016 number:1 pages:46-60 extent:15 |
| sourceStr |
Enthalten in Growth of organic benzimidazole (BMZ) single crystal by vertical Bridgman technique and its structural, spectral, thermal, optical, mechanical and dielectric properties New York, NY volume:167 year:2016 number:1 pages:46-60 extent:15 |
| format_phy_str_mv |
Article |
| bklname |
Sozialwissenschaften allgemein: Allgemeines Soziologie: Allgemeines |
| institution |
findex.gbv.de |
| topic_facet |
MMRV CDC RNA TCV APLs IgG DM CAPITA IBD SLE TNF IgM HPV SLEDAI HZ ASIA ANCA RNP ACIP Tdap GBS MBP HBV Hib PCV13 AD PBV MS EAE IS IL-10 VE RA ACR TGF MMR HIV EULAR PSV23 PCP DC |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Growth of organic benzimidazole (BMZ) single crystal by vertical Bridgman technique and its structural, spectral, thermal, optical, mechanical and dielectric properties |
| authorswithroles_txt_mv |
McKinnon, John E. @@aut@@ Maksimowicz-McKinnon, Kathleen @@oth@@ |
| publishDateDaySort_date |
2016-01-01T00:00:00Z |
| hierarchy_top_id |
ELV013179047 |
| dewey-sort |
3610 |
| id |
ELV035320710 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV035320710</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625203853.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.trsl.2015.08.008</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2016011000018.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV035320710</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1931-5244(15)00294-7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">530</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">620</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">670</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">300</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">70.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">71.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">McKinnon, John E.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Autoimmune disease and vaccination: impact on infectious disease prevention and a look at future applications</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">15</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Vaccines hold promise both for the prevention of infections and as potential immunologic therapy for patients with autoimmune disease (AD). These patients are at high risk for both common and opportunistic infections, but this risk can be significantly reduced and even obviated with the use of recommended available vaccines. Unfortunately, patients with ADs are not routinely offered or provided indicated vaccinations and have higher rates of complications from vaccine-preventable illnesses than patients without ADs. In addition, vaccine therapy is currently under study for the treatment of autoimmune disorders, with early studies demonstrating immunomodulatory effects that may counter undesired immune activation and alleviate disease activity.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Vaccines hold promise both for the prevention of infections and as potential immunologic therapy for patients with autoimmune disease (AD). These patients are at high risk for both common and opportunistic infections, but this risk can be significantly reduced and even obviated with the use of recommended available vaccines. Unfortunately, patients with ADs are not routinely offered or provided indicated vaccinations and have higher rates of complications from vaccine-preventable illnesses than patients without ADs. In addition, vaccine therapy is currently under study for the treatment of autoimmune disorders, with early studies demonstrating immunomodulatory effects that may counter undesired immune activation and alleviate disease activity.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MMRV</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CDC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">RNA</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">TCV</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">APLs</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">IgG</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">DM</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CAPITA</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">IBD</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SLE</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">TNF</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">IgM</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HPV</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SLEDAI</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HZ</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">ASIA</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">ANCA</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">RNP</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">ACIP</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Tdap</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">GBS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MBP</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HBV</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Hib</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PCV13</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">AD</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PBV</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">EAE</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">IS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">IL-10</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">VE</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">RA</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">ACR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">TGF</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MMR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HIV</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">EULAR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PSV23</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PCP</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">DC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Maksimowicz-McKinnon, Kathleen</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Muthuraja, A. ELSEVIER</subfield><subfield code="t">Growth of organic benzimidazole (BMZ) single crystal by vertical Bridgman technique and its structural, spectral, thermal, optical, mechanical and dielectric properties</subfield><subfield code="d">2015</subfield><subfield code="d">the journal of laboratory and clinical medicine : the official publication of the Central Society for Clinical Research</subfield><subfield code="g">New York, NY</subfield><subfield code="w">(DE-627)ELV013179047</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:167</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:46-60</subfield><subfield code="g">extent:15</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.trsl.2015.08.008</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">70.00</subfield><subfield code="j">Sozialwissenschaften allgemein: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">71.00</subfield><subfield code="j">Soziologie: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">167</subfield><subfield code="j">2016</subfield><subfield code="e">1</subfield><subfield code="h">46-60</subfield><subfield code="g">15</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
McKinnon, John E. |
| spellingShingle |
McKinnon, John E. ddc 610 ddc 530 ddc 620 ddc 670 ddc 300 bkl 70.00 bkl 71.00 Elsevier MMRV Elsevier CDC Elsevier RNA Elsevier TCV Elsevier APLs Elsevier IgG Elsevier DM Elsevier CAPITA Elsevier IBD Elsevier SLE Elsevier TNF Elsevier IgM Elsevier HPV Elsevier SLEDAI Elsevier HZ Elsevier ASIA Elsevier ANCA Elsevier RNP Elsevier ACIP Elsevier Tdap Elsevier GBS Elsevier MBP Elsevier HBV Elsevier Hib Elsevier PCV13 Elsevier AD Elsevier PBV Elsevier MS Elsevier EAE Elsevier IS Elsevier IL-10 Elsevier VE Elsevier RA Elsevier ACR Elsevier TGF Elsevier MMR Elsevier HIV Elsevier EULAR Elsevier PSV23 Elsevier PCP Elsevier DC Autoimmune disease and vaccination: impact on infectious disease prevention and a look at future applications |
| authorStr |
McKinnon, John E. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV013179047 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 530 - Physics 620 - Engineering & allied operations 670 - Manufacturing 300 - Social sciences |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 530 VZ 620 VZ 670 VZ 300 VZ 70.00 bkl 71.00 bkl Autoimmune disease and vaccination: impact on infectious disease prevention and a look at future applications MMRV Elsevier CDC Elsevier RNA Elsevier TCV Elsevier APLs Elsevier IgG Elsevier DM Elsevier CAPITA Elsevier IBD Elsevier SLE Elsevier TNF Elsevier IgM Elsevier HPV Elsevier SLEDAI Elsevier HZ Elsevier ASIA Elsevier ANCA Elsevier RNP Elsevier ACIP Elsevier Tdap Elsevier GBS Elsevier MBP Elsevier HBV Elsevier Hib Elsevier PCV13 Elsevier AD Elsevier PBV Elsevier MS Elsevier EAE Elsevier IS Elsevier IL-10 Elsevier VE Elsevier RA Elsevier ACR Elsevier TGF Elsevier MMR Elsevier HIV Elsevier EULAR Elsevier PSV23 Elsevier PCP Elsevier DC Elsevier |
| topic |
ddc 610 ddc 530 ddc 620 ddc 670 ddc 300 bkl 70.00 bkl 71.00 Elsevier MMRV Elsevier CDC Elsevier RNA Elsevier TCV Elsevier APLs Elsevier IgG Elsevier DM Elsevier CAPITA Elsevier IBD Elsevier SLE Elsevier TNF Elsevier IgM Elsevier HPV Elsevier SLEDAI Elsevier HZ Elsevier ASIA Elsevier ANCA Elsevier RNP Elsevier ACIP Elsevier Tdap Elsevier GBS Elsevier MBP Elsevier HBV Elsevier Hib Elsevier PCV13 Elsevier AD Elsevier PBV Elsevier MS Elsevier EAE Elsevier IS Elsevier IL-10 Elsevier VE Elsevier RA Elsevier ACR Elsevier TGF Elsevier MMR Elsevier HIV Elsevier EULAR Elsevier PSV23 Elsevier PCP Elsevier DC |
| topic_unstemmed |
ddc 610 ddc 530 ddc 620 ddc 670 ddc 300 bkl 70.00 bkl 71.00 Elsevier MMRV Elsevier CDC Elsevier RNA Elsevier TCV Elsevier APLs Elsevier IgG Elsevier DM Elsevier CAPITA Elsevier IBD Elsevier SLE Elsevier TNF Elsevier IgM Elsevier HPV Elsevier SLEDAI Elsevier HZ Elsevier ASIA Elsevier ANCA Elsevier RNP Elsevier ACIP Elsevier Tdap Elsevier GBS Elsevier MBP Elsevier HBV Elsevier Hib Elsevier PCV13 Elsevier AD Elsevier PBV Elsevier MS Elsevier EAE Elsevier IS Elsevier IL-10 Elsevier VE Elsevier RA Elsevier ACR Elsevier TGF Elsevier MMR Elsevier HIV Elsevier EULAR Elsevier PSV23 Elsevier PCP Elsevier DC |
| topic_browse |
ddc 610 ddc 530 ddc 620 ddc 670 ddc 300 bkl 70.00 bkl 71.00 Elsevier MMRV Elsevier CDC Elsevier RNA Elsevier TCV Elsevier APLs Elsevier IgG Elsevier DM Elsevier CAPITA Elsevier IBD Elsevier SLE Elsevier TNF Elsevier IgM Elsevier HPV Elsevier SLEDAI Elsevier HZ Elsevier ASIA Elsevier ANCA Elsevier RNP Elsevier ACIP Elsevier Tdap Elsevier GBS Elsevier MBP Elsevier HBV Elsevier Hib Elsevier PCV13 Elsevier AD Elsevier PBV Elsevier MS Elsevier EAE Elsevier IS Elsevier IL-10 Elsevier VE Elsevier RA Elsevier ACR Elsevier TGF Elsevier MMR Elsevier HIV Elsevier EULAR Elsevier PSV23 Elsevier PCP Elsevier DC |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
k m m kmm |
| hierarchy_parent_title |
Growth of organic benzimidazole (BMZ) single crystal by vertical Bridgman technique and its structural, spectral, thermal, optical, mechanical and dielectric properties |
| hierarchy_parent_id |
ELV013179047 |
| dewey-tens |
610 - Medicine & health 530 - Physics 620 - Engineering 670 - Manufacturing 300 - Social sciences, sociology & anthropology |
| hierarchy_top_title |
Growth of organic benzimidazole (BMZ) single crystal by vertical Bridgman technique and its structural, spectral, thermal, optical, mechanical and dielectric properties |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV013179047 |
| title |
Autoimmune disease and vaccination: impact on infectious disease prevention and a look at future applications |
| ctrlnum |
(DE-627)ELV035320710 (ELSEVIER)S1931-5244(15)00294-7 |
| title_full |
Autoimmune disease and vaccination: impact on infectious disease prevention and a look at future applications |
| author_sort |
McKinnon, John E. |
| journal |
Growth of organic benzimidazole (BMZ) single crystal by vertical Bridgman technique and its structural, spectral, thermal, optical, mechanical and dielectric properties |
| journalStr |
Growth of organic benzimidazole (BMZ) single crystal by vertical Bridgman technique and its structural, spectral, thermal, optical, mechanical and dielectric properties |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 500 - Science 300 - Social sciences |
| recordtype |
marc |
| publishDateSort |
2016 |
| contenttype_str_mv |
zzz |
| container_start_page |
46 |
| author_browse |
McKinnon, John E. |
| container_volume |
167 |
| physical |
15 |
| class |
610 610 DE-600 530 VZ 620 VZ 670 VZ 300 VZ 70.00 bkl 71.00 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
McKinnon, John E. |
| doi_str_mv |
10.1016/j.trsl.2015.08.008 |
| dewey-full |
610 530 620 670 300 |
| title_sort |
autoimmune disease and vaccination: impact on infectious disease prevention and a look at future applications |
| title_auth |
Autoimmune disease and vaccination: impact on infectious disease prevention and a look at future applications |
| abstract |
Vaccines hold promise both for the prevention of infections and as potential immunologic therapy for patients with autoimmune disease (AD). These patients are at high risk for both common and opportunistic infections, but this risk can be significantly reduced and even obviated with the use of recommended available vaccines. Unfortunately, patients with ADs are not routinely offered or provided indicated vaccinations and have higher rates of complications from vaccine-preventable illnesses than patients without ADs. In addition, vaccine therapy is currently under study for the treatment of autoimmune disorders, with early studies demonstrating immunomodulatory effects that may counter undesired immune activation and alleviate disease activity. |
| abstractGer |
Vaccines hold promise both for the prevention of infections and as potential immunologic therapy for patients with autoimmune disease (AD). These patients are at high risk for both common and opportunistic infections, but this risk can be significantly reduced and even obviated with the use of recommended available vaccines. Unfortunately, patients with ADs are not routinely offered or provided indicated vaccinations and have higher rates of complications from vaccine-preventable illnesses than patients without ADs. In addition, vaccine therapy is currently under study for the treatment of autoimmune disorders, with early studies demonstrating immunomodulatory effects that may counter undesired immune activation and alleviate disease activity. |
| abstract_unstemmed |
Vaccines hold promise both for the prevention of infections and as potential immunologic therapy for patients with autoimmune disease (AD). These patients are at high risk for both common and opportunistic infections, but this risk can be significantly reduced and even obviated with the use of recommended available vaccines. Unfortunately, patients with ADs are not routinely offered or provided indicated vaccinations and have higher rates of complications from vaccine-preventable illnesses than patients without ADs. In addition, vaccine therapy is currently under study for the treatment of autoimmune disorders, with early studies demonstrating immunomodulatory effects that may counter undesired immune activation and alleviate disease activity. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U |
| container_issue |
1 |
| title_short |
Autoimmune disease and vaccination: impact on infectious disease prevention and a look at future applications |
| url |
https://doi.org/10.1016/j.trsl.2015.08.008 |
| remote_bool |
true |
| author2 |
Maksimowicz-McKinnon, Kathleen |
| author2Str |
Maksimowicz-McKinnon, Kathleen |
| ppnlink |
ELV013179047 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth |
| doi_str |
10.1016/j.trsl.2015.08.008 |
| up_date |
2024-07-06T17:15:39.974Z |
| _version_ |
1803850759513571328 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV035320710</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625203853.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.trsl.2015.08.008</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2016011000018.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV035320710</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1931-5244(15)00294-7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">530</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">620</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">670</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">300</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">70.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">71.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">McKinnon, John E.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Autoimmune disease and vaccination: impact on infectious disease prevention and a look at future applications</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">15</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Vaccines hold promise both for the prevention of infections and as potential immunologic therapy for patients with autoimmune disease (AD). These patients are at high risk for both common and opportunistic infections, but this risk can be significantly reduced and even obviated with the use of recommended available vaccines. Unfortunately, patients with ADs are not routinely offered or provided indicated vaccinations and have higher rates of complications from vaccine-preventable illnesses than patients without ADs. In addition, vaccine therapy is currently under study for the treatment of autoimmune disorders, with early studies demonstrating immunomodulatory effects that may counter undesired immune activation and alleviate disease activity.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Vaccines hold promise both for the prevention of infections and as potential immunologic therapy for patients with autoimmune disease (AD). These patients are at high risk for both common and opportunistic infections, but this risk can be significantly reduced and even obviated with the use of recommended available vaccines. Unfortunately, patients with ADs are not routinely offered or provided indicated vaccinations and have higher rates of complications from vaccine-preventable illnesses than patients without ADs. In addition, vaccine therapy is currently under study for the treatment of autoimmune disorders, with early studies demonstrating immunomodulatory effects that may counter undesired immune activation and alleviate disease activity.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MMRV</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CDC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">RNA</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">TCV</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">APLs</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">IgG</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">DM</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CAPITA</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">IBD</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SLE</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">TNF</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">IgM</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HPV</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SLEDAI</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HZ</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">ASIA</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">ANCA</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">RNP</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">ACIP</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Tdap</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">GBS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MBP</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HBV</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Hib</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PCV13</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">AD</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PBV</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">EAE</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">IS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">IL-10</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">VE</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">RA</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">ACR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">TGF</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MMR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HIV</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">EULAR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PSV23</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PCP</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">DC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Maksimowicz-McKinnon, Kathleen</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Muthuraja, A. ELSEVIER</subfield><subfield code="t">Growth of organic benzimidazole (BMZ) single crystal by vertical Bridgman technique and its structural, spectral, thermal, optical, mechanical and dielectric properties</subfield><subfield code="d">2015</subfield><subfield code="d">the journal of laboratory and clinical medicine : the official publication of the Central Society for Clinical Research</subfield><subfield code="g">New York, NY</subfield><subfield code="w">(DE-627)ELV013179047</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:167</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:46-60</subfield><subfield code="g">extent:15</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.trsl.2015.08.008</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">70.00</subfield><subfield code="j">Sozialwissenschaften allgemein: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">71.00</subfield><subfield code="j">Soziologie: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">167</subfield><subfield code="j">2016</subfield><subfield code="e">1</subfield><subfield code="h">46-60</subfield><subfield code="g">15</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.399722 |